Envoy Medical, Inc. (COCH) Expected to Beat Earnings Estimates: Should You Buy?

Core Viewpoint - The market anticipates Envoy Medical, Inc. (COCH) to report a year-over-year increase in earnings despite flat revenues for the quarter ending September 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The consensus EPS estimate for Envoy Medical is a loss of $0.27 per share, reflecting a year-over-year change of +27% [3]. - Revenues are projected to remain unchanged at $0.06 million compared to the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 9.09% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +11.11%, suggesting a bullish outlook on earnings [12]. Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - Envoy Medical holds a Zacks Rank of 2, enhancing the likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Envoy Medical was expected to post a loss of $0.29 per share but actually reported a loss of -$0.32, resulting in a surprise of -10.34% [13]. - Over the past four quarters, the company has only beaten consensus EPS estimates once [14]. Industry Context - In the Zacks Medical - Instruments industry, 908 Devices Inc. is expected to report a loss of $0.13 per share for the same quarter, indicating a year-over-year change of +43.5% [18]. - 908 Devices' revenue is projected to decline by 19% to $13.58 million, with a consensus EPS estimate revised 6.3% lower, resulting in an Earnings ESP of -18.42% [19][20].